[Mortality rates in pediatric septic shock secondary to community-acquired infection: about 70 cases].
OBJECTIVE
This study had for aim to determine the mortality rate and the factors affecting mortality among 70 children admitted for septic shock secondary to a community acquired infection.


METHODS
A retrospective analysis was made of patients admitted between January 1998 and August 2005, in a pediatric ICU for septic shock secondary to a community-acquired infection. Neonates under 7 days of age were excluded from the study.


RESULTS
Seventy cases were included and 32 (45.7 %) of them died. Their average age was 3.8+/-4.2 years and their PRISM during the first 24 hours was 19.2+/-8.4. Sixty-nine children (98.6 %) presented with multivisceral failure and 60 (85.7 %) with more than two deficient organs. The average time between the observation of first hemodynamic disorders and admission to ICU was 9.4+/-11.3 hours. Three independent mortality risk factors were identified: failure of more than two organs on admission (OR, 4.4; 95 % CI [2.1-9.4]), an infusion volume superior to 20ml/kg on the second day of resuscitation (OR, 3.4; 95 CI % [1.1-10.3]), and the use of more than two vasoactive drugs (OR, 3.3; 95 CI % [1.2-9]).
Menif
K
K
Service de réanimation pédiatrique polyvalente, hôpital d'enfants de Tunis, place Bab-Saadoun-Jebbari, Tunis, Tunisie. menifk@yahoo.fr
Khaldi
A
A
Bouziri
A
A
Kechaou
W
W
Belhadj
S
S
Hamdi
A
A
Kazdaghli
K
K
Benjaballah
N
N
D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000150:complications*; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D005440:Fluid Therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009102:Multiple Organ Failure / Q000209:etiology / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D012772:Shock, Septic / Q000209:etiology / Q000401:mortality* / Q000628:therapy; D014416:Tunisia / Q000453:epidemiology; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D014662:Vasoconstrictor Agents; D004837:Epinephrine